Ascletis Pharma Debuts in Hong Kong

The video discusses the significance of the first biotech company listing on the Hong Kong Stock Exchange, highlighting a new drug approval by China FDA. It examines IPO subscription trends, noting a reliance on institutional buyers due to low retail demand. The outlook for Hong Kong's IPO market is considered, with a focus on attracting more listings. Future biotech listings and the pricing of China Tower are also discussed, with potential implications for the market.

What is the significance of the first biotech company being listed on the Hong Kong Stock Exchange?

• It marks the first time a tech company is listed.

• It is the first biotech company to be listed.

• It is the largest company ever listed.

• It is the first company to list without an IPO.

What challenge is mentioned regarding IPOs in Hong Kong?

• High retail demand

• Lack of institutional interest

• Insufficient retail demand

• Excessive government regulation

How much of the IPOs are typically subscribed by institutional buyers?

• 90%

• 70%

• 50%

• 10%

What is the outlook for biotech companies in the Hong Kong IPO market?

• There is a declining interest.

• The market is closed to new biotech companies.

• There is a healthy pipeline of upcoming listings.

• There are no new companies filing for IPOs.

What is the current status of the China Tower deal?

• It has been postponed indefinitely.

• It is still being priced.

• It is already priced.

• It has been canceled.